Table 1 Overview of seroprevalence estimates between October 2020 and March 2021
Period | SARS-CoV-2 serology test result | Seroprevalence (95% CI) standandardized by age and sex for national population | p value | |
|---|---|---|---|---|
Total n | Positive n (%) | |||
October 2020– November 2020 | 3626 | 1025 (28.3%) | 27.9% (26.1–29.7) | p < 0.001 |
December 2020– January 2021 | 6880 | 2984 (43.4%) | 42.2% (40.8–43.5) | |
February 2021– March 2021 | 19,548 | 10,052 (51.4%) | 51.0% (50.3–51.8) | |
Total | 30,054 | 14,061 (46.8%) | 46.4% (45.8–47.0) | |
